Danno Pharmaceuticals was incorporated in 2013 and is a biotechnology company nearing commercialization. It focuses on the discovery, development, and commercialization of differentiated innovative drug products to address unmet clinical needs in the areas of bacterial infections and bacterial metabolism‑related diseases. Leveraging its proprietary multi‑target conjugate molecule technology, Danno is committed to delivering optimal treatment options that overcome the limitations of conventional therapies and improve patient outcomes. As of January 24, 2026, Danno has established a pipeline comprising seven innovative programs, including two core products: TNP‑2198, a novel molecular entity (NME) candidate currently being evaluated in China and the United States as part of a triple‑therapy regimen—combined with amoxicillin and a proton pump inhibitor—for the treatment of Helicobacter pylori infection, and also as a monotherapy in China for bacterial vaginosis and Clostridioides difficile infection; and TNP‑2092 injection, a three‑target therapeutic candidate indicated for implant‑associated bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and prosthetic joint infections (PJI), as well as for the treatment of left ventricular assist device‑associated infections (LVADI) and central venous catheter‑related bloodstream infections (CRBSI) in both China and the United States.